 |
      
|
|
|
|
|
|||||
|
|
July 15, 2004
Neurochem to present findings at the 9th International Conference on Alzheimer's Disease
and Related Disorders. Oral Presentations |
|
|
What |
Alzhemed™ interim clinical results in mild-to-moderate AD patients (open-label extended study) |
|
|
Who |
Dr. Paul Aisen, Professor of Neurology and Medicine at Georgetown University Medical Center in Washington, D.C. and principal investigator in the United States for the Phase III study on Alzhemed™ |
|
|
When |
Sunday, July 18 |
|
|
Event |
Therapeutics-1 |
|
|
Location |
Room 204 ABC |
|
|
What |
Targeting GAGs for Treatment of Alzheimer's Disease within the Symposium: Current Progress on Development of Therapeutic Strategies Based Upon the Amyloid Hypothesis |
|
|
Who |
Francine Gervais, Ph.D., Vice-President, Research and Development, Neurochem Inc. |
|
|
When |
Monday, July 19 |
|
|
Event |
Current Progress on Development of Therapeutic Strategies Based Upon the Amyloid Hypothesis |
|
|
Location |
Ballroom A/B |
|
|
Poster Presentations |
||
|
What |
"Age Modulates the Vulnerability of Rat Neuronal Cultures to Aß-Induced Cell Death" |
|
|
Who |
Morissette, Céline, et al. |
|
|
When |
Tuesday, July 20 |
|
|
Location |
Hall B |
|
|
What |
"Zwitterionic Compounds Promote Conformationally and Morphologically Unique Changes in the Aß Peptide" |
|
|
Who |
McLaughlin, Richard, et al. |
|
|
When |
Wednesday, July 21 |
|
|
Location |
Hall B |
|
|
Neurochem will be on-site at its corporate booth (#109) from Monday, July 19th, through to
Wednesday, July 21st, to meet anyone interested in learning more about the Company's programs and
to answer any questions. About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for
neurological disorders. The Company's pipeline of proprietary, disease-modifying, oral products
addresses critical, unmet medical needs. Fibrillex™, designated as an orphan drug and a Fast
Track Product candidate, is also part of a Continuous Marketing Applications Pilot 2 program and is
currently in a Phase II/III clinical trial for the treatment of AA Amyloidosis. Alzhemed™, for
the treatment of Alzheimer's Disease, is in a Phase III clinical trial and Cerebril™, for the
prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase II
clinical trial. To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North
American toll-free number 1-877-680-4500 or visit our website at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact that are
independently verifiable at the date hereof, may constitute forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control.
Such risks include but are not limited to: the impact of general economic conditions, general
conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions
in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation as well as other risks included in public filings
of Neurochem. Consequently, actual future results may differ materially from the anticipated
results expressed in the forward-looking statements. The reader should not place undue reliance on
the forward-looking statements included in this news release. These statements speak only as of
the date made and Neurochem is under no obligation and disavows any intention to update or revise
such statements as a result of any event, circumstances or otherwise. |
||
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
